Compare Cigna Corp (CI) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs FMC Corp — how do they compare? Cigna Corp trades at $300.34 (market cap $80.25B), while FMC Corp trades at $10.67 (market cap $1.34B). The key difference: Cigna Corp is far larger — about 59.9× FMC Corp's market cap, and FMC Corp pays the higher dividend (2.99%). Which is the better fit depends on your goals.
| CI | FMC | |
|---|---|---|
Market Cap | $80.25B | $1.34B |
Sector | Health | Basic Materials |
52-Week High | $311.00 | $43.90 |
52-Week Low | $244.41 | $10.72 |
Enterprise Value | $103.35B | $5.49B |
Dividend Yield | 2.06% | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
FMC Corporation (FMC) trades at $10.91 with no change in the latest session. The agricultural sciences company shows mixed signals with a bearish technical outlook but positive analyst sentiment (47.6% buy ratings). Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submissions for new herbicide technology. However, fundamental challenges persist with negative net income margin of -72.93% and declining revenue from $5.8B in 2022 to $3.47B in 2025.
The stock presents a turnaround opportunity with attractive valuation metrics (P/S 0.4x, P/B 0.75x) and significant upside to the $16 consensus price target. Key risks include continued revenue declines, negative cash flow from operations, and high debt levels. The company's strategic moves to reduce debt and advance new products could drive recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
